Results of interferon-alfa therapy in patients with Behcet uveitis

被引:111
|
作者
Tugal-Tutkun, Ilknur [1 ]
Guney-Tefekli, Esra [1 ]
Urgancioglu, Meri [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, Istanbul, Turkey
关键词
Behcet disease; interferon-alpha; 2a; uveitis;
D O I
10.1007/s00417-006-0346-y
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report on the results of interferon-alpha 2a (IFN alpha) treatment in patients with Behcet uveitis unresponsive to conventional immunosuppressive therapy. Methods: We retrospectively analyzed the medical records of 44 patients who had been treated with IFN alpha between September 2001 and May 2005. The initial dose of IFN alpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity. Results: Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4 +/- 10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2 +/- 13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6 +/- 1.2 to 0.8 +/- 0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFN alpha therapy (p < 0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients. Conclusions: A partial or complete response was obtained with IFN alpha therapy in 91% of Turkish patients with Behcet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFN alpha in different patient populations. Comparative studies are needed to investigate this hypothesis.
引用
收藏
页码:1692 / 1695
页数:4
相关论文
共 50 条
  • [1] INTERFERON-ALFA THERAPY IN TURKISH PATIENTS WITH BEHCET UVEITIS
    Tugal-Tutkun, Ilknur
    Araz, Bilge
    Aydinoglu-Candan, Ozlem
    Ersan, Mehmet Cemal
    Uludag, Gunay
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S144 - S144
  • [2] Results of interferon-alfa therapy in patients with Behçet uveitis
    Ilknur Tugal-Tutkun
    Esra Güney-Tefekli
    Meri Urgancioglu
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244 : 1692 - 1695
  • [3] The use of interferon-alfa in Behcet's disease:: review of the literature
    Kötter, I
    Günaydin, I
    Zierhut, M
    Stübiger, N
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 2) : S2 - S2
  • [4] EFFECT OF INTERFERON-ALFA 2A THERAPY ON PERIPHERAL BLOOD CD4+CD25+T REGULATORY CELLS IN PATIENTS WITH BEHCET'S UVEITIS
    Koc, Aylin
    Onal, Sumru
    Kazokoglu, Haluk
    Tolunay, Aysin
    Demiralp, Emel
    Direskeneli, Haner
    Yavuz, Sule
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S122 - S122
  • [5] Neuropsychiatric side effects of interferon-alfa therapy
    Van Gool, AR
    Kruit, WHJ
    Engels, FK
    Stoter, G
    Bannink, M
    Eggermont, AMM
    PHARMACY WORLD & SCIENCE, 2003, 25 (01): : 11 - 20
  • [6] REVERSIBLE HYPOPITUITARISM AFTER INTERFERON-ALFA THERAPY
    SAKANE, N
    YOSHIDA, T
    YOSHIOKA, K
    UMEKAWA, T
    KONDO, M
    SHIMATSU, A
    LANCET, 1995, 345 (8960): : 1305 - 1305
  • [7] MYASTHENIA-GRAVIS DURING INTERFERON-ALFA THERAPY
    BATOCCHI, AP
    EVOLI, A
    SERVIDEI, S
    PALMISANI, MT
    APOLLO, F
    TONALI, P
    NEUROLOGY, 1995, 45 (02) : 382 - 383
  • [8] Comparison of the treatment results for Behcet uveitis in patients treated with infliximab and interferon
    Yalcindag, Nilufer
    Kose, Helin Ceren
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (02) : 305 - 314
  • [9] Comparison of the treatment results of infliximab and interferon alpha in patients with Behcet uveitis
    Degirmenci, M. F. K.
    Kose, H. C.
    Yalcindag, N.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : S175 - S175
  • [10] Interferon Alpha-2a Therapy in Patients with Refractory Behcet Uveitis
    Hasanreisoglu, Murat
    Cubuk, Mehmet Ozgur
    Ozdek, Sengul
    Gurelik, Gokhan
    Aktas, Zeynep
    Hasanreisoglu, Berati
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2017, 25 (01) : 71 - 75